Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$75.82 - $150.97 $3.72 Million - $7.4 Million
-49,000 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$132.01 - $190.29 $6.47 Million - $9.32 Million
49,000 New
49,000 $7.19 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Cibc World Markets Corp Portfolio

Follow Cibc World Markets Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc World Markets Corp, based on Form 13F filings with the SEC.

News

Stay updated on Cibc World Markets Corp with notifications on news.